Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Virus vs. superbug: experimental therapy targets Drug-Resistant lung infection

NCT ID NCT07228702

Disease control Sponsor: Vancouver Coastal Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a special virus called a bacteriophage, combined with standard antibiotics, to treat a severe lung infection caused by Mycobacterium abscessus. The trial involves just one patient and aims to see if the virus can help clear the infection. It is an early, personalized approach for a condition that is very hard to treat.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Mycobacteriophage Muddy_HRMN0052 (a virus that attacks bacteria) plus standard antibiotics (amikacin, clofazimine, bedaquiline, linezolid)
What this could lead to
If it works, this could point toward a new treatment option for people with stubborn lung infections that don't respond to standard antibiotics.
What could go wrong
This is a very early study in just one person, so results may not apply to others. The treatment may not work, and there are risks from both the phage and the strong antibiotics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 1 person

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

This is an individual patient expanded access study specific to one individual based on tailor intervention (Mycobacteriophage) Inclusion Criteria: * consent to participation Exclusion Criteria: * non-consent to participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mycobacterium abscessus infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung disorder mycobacterial infectious disease Mycobacterium Infections, Nontuberculous pneumonia pulmonary non-tuberculous mycobacterial infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mycobacterium abscessus infection Non-tuberculous mycobacterial (NTM) pneumonia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Vancouver General Hospital Non-Tuberculous Mycobacterial Disease Clinic

    Vancouver, British Columbia, V5Z 1M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.